Overview

Drug-drug Interaction Study of Digoxin and AT-527 (R07496998)

Status:
Not yet recruiting
Trial end date:
2021-11-01
Target enrollment:
0
Participant gender:
All
Summary
Drug-drug interaction study of Digoxin and AT-527 (R07496998)
Phase:
Phase 1
Accepts Healthy Volunteers?
Accepts Healthy Volunteers
Details
Lead Sponsor:
Atea Pharmaceuticals, Inc.
Collaborator:
Hoffmann-La Roche
Treatments:
Digoxin
Criteria
Inclusion Criteria:

- Must agree to use two methods of birth control from Screening through 90 days after
administration of the last dose of study drug

- Females must have a negative pregnancy test at Screening and prior to dosing

- Minimum body weight of 50 kg and body mass index (BMI) of 18-32 kg/m2

- Willing to comply with the study requirements and to provide written informed consent

Exclusion Criteria:

- Infected with hepatitis B virus, hepatitis C virus, HIV or SARS-CoV-2

- Abuse of alcohol or drugs

- Use of other investigational drugs within 28 days of dosing

- Concomitant use of prescription medications, or systemic over-the-counter medications

- Other clinically significant medical conditions or laboratory abnormalities